AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$61.15
neg -0.23
-0.37%
Today's Range: 61.08 - 61.77 | ABBV Avg Daily Volume: 8,385,500
Last Update: 01/20/17 - 3:59 PM EST
Volume: 6,605,446
YTD Performance: -1.98%
Open: $61.41
Previous Close: $61.38
52 Week Range: $51.60 - $68.12
Oustanding Shares: 1,625,099,012
Market Cap: 100,528,624,882
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 5 4 6
Moderate Buy 1 1 1 1
Hold 8 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.50 2.40 2.50 2.27
Latest Dividend: 0.64
Latest Dividend Yield: 4.15%
Dividend Ex-Date: 01/11/17
Price Earnings Ratio: 16.66
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
16.66 16.70 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.08% 11.62% 22.61%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 184.50 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.25 $4.82 $5.49
Number of Analysts 10 3 11 9
High Estimate $1.26 $1.28 $4.85 $5.53
Low Estimate $1.17 $1.21 $4.80 $5.44
Prior Year $1.13 $1.15 $4.29 $4.82
Growth Rate (Year over Year) 6.11% 8.99% 12.40% 13.93%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Biotech Just Got Trumped Real Money Pro($)

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.
Overall, the next move for ABBV looks like it will be to the upside.
What stocks have changed direction in the past week.
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Bearish
Oct 31, 2016 | 8:19 AM EDT
ABBV was downgraded from Outperform to Neutral, Credit Suisse said. $60 price target. Humira longevity concerns are increasing.

Columnist Conversations

we are picking this up with the bullish flow, strong volume and decent chart BOUGHT MDLZ APR 4...
IBM (IBM)  reported numbers last night that, as expected, came in ahead of Wall Street consensus but were...
That 9.09% NYC MTA increase.... not reflected in your COLA (cost of living adjustment) for Social Security, or...
EMN put in its third straight monthly high last week.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.